The stock price of Astrazeneca plc ADR (NASDAQ: AZN) has dropped by -0.75 compared to previous close of 69.45. Despite this, the company has seen a gain of 2.19% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-12 that The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it’s a secondary consideration.
Is It Worth Investing in Astrazeneca plc ADR (NASDAQ: AZN) Right Now?
The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is 36.12x, which is above its average ratio. Moreover, the 36-month beta value for AZN is 0.53. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B and currently, short sellers hold a 0.25% of that float. On April 15, 2024, AZN’s average trading volume was 6.27M shares.
AZN’s Market Performance
AZN stock saw an increase of 2.19% in the past week, with a monthly gain of 2.00% and a quarterly increase of -0.36%. The volatility ratio for the week is 1.24%, and the volatility levels for the last 30 days are 1.31% for Astrazeneca plc ADR (AZN).. The simple moving average for the past 20 days is 2.81% for AZN’s stock, with a 3.42% simple moving average for the past 200 days.
Analysts’ Opinion of AZN
Morgan Stanley, on the other hand, stated in their research note that they expect to see AZN reach a price target of $85. The rating they have provided for AZN stocks is “Overweight” according to the report published on January 23rd, 2024.
AZN Trading at 4.68% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.97% of loss for the given period.
Volatility was left at 1.31%, however, over the last 30 days, the volatility rate increased by 1.24%, as shares surge +2.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.44% upper at present.
During the last 5 trading sessions, AZN rose by +2.19%, which changed the moving average for the period of 200-days by -3.82% in comparison to the 20-day moving average, which settled at $67.14. In addition, Astrazeneca plc ADR saw 2.35% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.82 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.12. Equity return is now at value 15.63, with 6.03 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.36. The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is 5.13.
Currently, EBITDA for the company is 13.91 billion with net debt to EBITDA at 1.8. When we switch over and look at the enterprise to sales, we see a ratio of 5.16. The receivables turnover for the company is 3.38for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
To wrap up, the performance of Astrazeneca plc ADR (AZN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
